Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04745195
Other study ID # NL74928.068.20
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 12, 2021
Est. completion date August 31, 2024

Study information

Verified date August 2021
Source Maastricht University Medical Center
Contact Pieter van Paassen, MD, PhD
Phone +31(0)433871198
Email p.vanpaassen@maastrichtuniversity.nl
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various clinical conditions. Dysregulation of the alternative pathway of complement may be the etiological factor and this type of TMA is classified, according to the current nomenclature, as primary atypical hemolytic uremic syndrome (HUS). Half the patients with primary atypical HUS present with rare variants in complement genes, although coexisting conditions are often needed for the TMA to become manifest. In patients with secondary atypical HUS, certain coexisting conditions appear to drive the disease and treatment should target the underlying condition to remit the TMA. Recently, the investigators demonstrated, by using a novel in-house developed functional endothelial cell-based test, that complement dysregulation and overactivation is the dominant cause of disease and its sequelae in a subset of patients with secondary atypical HUS, having impact on treatment and prognosis. The investigators did first prove this concept in patients presenting with TMA and hypertensive emergency. A prospective study is needed to further corroborate these findings along the spectrum of TMA. The investigators hypothesize that their functional endothelial cell-based test, the so-called "HMEC" test, can better categorizes the TMA into different groups with potential therapeutic and prognostic implications. Thus, paving the road to the ultimate goal of precision medicine.


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date August 31, 2024
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Males or females at least 18 years of age; - Have acute kidney injury, defined as estimated GFR <45 mL/min/1.73m2; - Have documented TMA either on peripheral blood, defined as Coombs negative microangiopathic hemolytic anemia (hematocrit <30%, hemoglobin <6.5 mmol/L [<10 g/dL], lactate dehydrogenase >500 U/L, and either schistocytes on peripheral blood smear or undetectable haptoglobin), and platelets <150,000 per µL, or kidney biopsy; - Have primary atypical HUS or a coexisting condition linked to complement dysregulation: - Hypertensive emergency, defined as SBP/DBP of >180/120 mmHg and impending organ damage secondary to hypertension (at least one of the following: neurologic disease, hypertensive retinopathy grade III and/or IV, left ventricular hypertrophy); OR - Pregnancy, including 12 weeks postpartum; OR - Kidney donor recipient; OR - Systemic auto-immune disease associated with TMA, including systemic sclerosis, systemic lupus erythematosus, anti-phospholipid syndrome; - Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures. Exclusion Criteria: - Have secondary causes of hypertensive emergency, including renovascular hypertension, Cushing syndrome, aldosteronism, pheochromocytoma, thyroid disease; - Have a nephropathy not related to thrombosis on kidney biopsy; - Have ADAMTS13 deficiency, defined as ADAMTS13 activity <10%; - Have a positive stool culture for Shiga toxin producing bacteria; - Have positive serologic test for viral infections, including HIV and CMV; - Have a history of malignant disease, excluding non-melanoma skin cancer; - Have a history of bone marrow or solid organ transplantation, excluding kidney transplantation; - Received at least one of the following agents: chemotherapeutics, sirolimus, anti-VEGF agents; - Have a history of recent past exposure to illicit drug(s).

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands Maastricht University Medical Center Maastricht Limburg

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary The prevalence of complement-mediated TMA along the spectrum of TMA 1 year
Secondary The diagnostic performance of the "HMEC" test for the diagnosis of complement-mediated TMA 1 year
Secondary The dynamics of ex vivo C5b9 formation on the endothelium during the course of TMA every month for up to 1 year
Secondary The dynamics of ex vivo C5b9 formation on the endothelium as compared to routine complement measures during the course of TMA every month for up to 1 year
Secondary Composite kidney endpoint: 50% eGFR decline, chronic kidney disease stage G5, end-stage kidney disease The diagnostic and prognostic value of pathologic features and chronicity indices on kidney biopsy at the time of presentation 1 year
Secondary composite TMA endopoint: TMA recurrence, end-stage kidney disease The prognostic value of genetic variants in complement genes 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04098445 - TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Not yet recruiting NCT05996679 - Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study
Completed NCT02222545 - Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies Phase 2
Recruiting NCT06102694 - Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
Completed NCT03252925 - A Safety and Efficacy Study of NAC in Patients With TA-TMA Phase 3
Recruiting NCT05855083 - Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA Phase 2
Completed NCT03384693 - Defibrotide TMA Prophylaxis Pilot Trial Phase 2
Not yet recruiting NCT05702996 - Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies Phase 3
Not yet recruiting NCT02373267 - Screening of TMA Patients für ADAMTS13 Activity (Adamscreen) N/A
Recruiting NCT06098378 - Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab
Completed NCT02134171 - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA N/A
Not yet recruiting NCT06182410 - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma Phase 2
Withdrawn NCT04970004 - Study in Adult and Pediatric Patients With HSCT-TMA
Recruiting NCT03205995 - Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Phase 3
Recruiting NCT04784455 - Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy Phase 3
Active, not recruiting NCT04570397 - Ravulizumab and COVID-19 Phase 3
Recruiting NCT05634928 - Construction of a Database for TMA
Completed NCT03518203 - Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Phase 2
Recruiting NCT06291415 - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) Phase 1